Cleared Traditional

K052007 - ABX PENTRA 400 CLINICAL CHEMISTRY ANALYZER (OPTION: I.S.E. MODULE)

K052007 is an FDA 510(k) clearance for ABX PENTRA 400 CLINICAL CHEMISTRY ANALY..., manufactured by Horiba Abx. The device is a Class 2 Chemistry device with product code CFR cleared through the Traditional 510(k) pathway after a 144-day FDA review.

K052007 · Horiba Abx · Chemistry device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Dec 2005
Decision
144d
Days
Class 2
Risk

K052007 is an FDA 510(k) clearance for the ABX PENTRA 400 CLINICAL CHEMISTRY ANALYZER (OPTION: I.S.E. MODULE). Classified as Hexokinase, Glucose (product code CFR), Class II - Special Controls.

Submitted by Horiba Abx (Montpellier, FR). The FDA issued a Cleared decision on December 16, 2005 after a review of 144 days - within the typical 510(k) review window.

This device falls under the Chemistry FDA review panel, regulated under 21 CFR 862.1345 - the FDA in vitro diagnostics and chemistry framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Standard predicate reliance. This clearance follows a standard predicate-based equivalence path within the Chemistry review framework, consistent with the majority of Class II 510(k) submissions.

View all Horiba Abx devices

FDA 510(k) Submission Details - K052007

510(k) Number K052007 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received July 25, 2005
Decision Date December 16, 2005
Days to Decision 144 days
Submission Type Traditional
Review Panel Chemistry (CH)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
56d slower than avg
Panel avg: 88d · This submission: 144d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

CFR Device Classification - Class 2, Special Controls

Product Code CFR Hexokinase, Glucose
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 862.1345
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Chemistry devices follow this clearance model.

Regulatory Peers - CFR Hexokinase, Glucose

All 136
Devices cleared under the same product code (CFR) and FDA review panel - the closest regulatory comparables to K052007.
COBAS INTEGRA GLUCOSE HK GEN. 3 TEST SYSTEM
K061048 · Roche Diagnostics Corp. · May 2006
GLUCOSE
K060383 · Abbott Laboratories · May 2006
UNICEL DXC 600I SYNCHRON ACCESS CLINICAL SYSTEM
K060256 · Beckman Coulter, Inc. · Feb 2006
ADVIA IMS GLUCOSE ASSAY
K052163 · Bayer Healthcare, LLC · Oct 2005
DATAPRO CLINICAL CHELISTRY ANALYZER
K042767 · Thermo Electron Corporation · Apr 2005
RAICHEM GLUCOSE UV (LIQUID)
K041052 · Hemagen Diagnostics, Inc. · Jun 2004